Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | 11.49%1.84M | -34.60%1.15M | -37.39%2.38M | -21.13%2.94M | -25,252.94%-4.28M | 9,829.41%1.65M | 25.23%1.76M | 63.78%3.8M | 169.82%3.73M | 100.38%17K |
| Net profit before non-cash adjustment | 656.66%1.97M | 101.59%1.78M | 262.67%719K | -67.46%872K | -60.17%785K | 82.09%-353K | -69.49%882K | -109.48%-442K | -38.57%2.68M | 59.72%1.97M |
| Total adjustment of non-cash items | 287.01%144K | -26.36%176K | 111.32%224K | 195.83%710K | 258.99%442K | -127.70%-77K | 251.47%239K | -38.37%106K | -50.21%240K | -208.89%-278K |
| -Depreciation and amortization | 125.23%250K | -32.62%252K | -1.94%253K | 3.65%995K | 4.56%252K | 146.06%111K | -48.13%374K | 7.95%258K | 5.61%960K | 3.43%241K |
| -Reversal of impairment losses recognized in profit and loss | 1,000.00%9K | 3,900.00%40K | --81K | 223.70%167K | 219.29%167K | -100.71%-1K | 100.74%1K | --0 | -694.12%-135K | -636.84%-140K |
| -Disposal profit | 47.17%-112K | -375.00%-114K | -31.25%-105K | -66.93%-429K | -56.94%-113K | -394.44%-212K | 88.12%-24K | -45.45%-80K | 11.68%-257K | 65.05%-72K |
| -Net exchange gains and losses | --0 | --2K | --0 | 109.02%24K | 109.02%24K | -79.70%54K | --0 | ---54K | -236.71%-266K | -291.18%-266K |
| -Other non-cash items | 89.66%-3K | 96.43%-4K | 72.22%-5K | 24.19%-47K | 609.09%112K | -231.82%-29K | -124.00%-112K | -50.00%-18K | -55.00%-62K | 26.67%-22K |
| Changes in working capital | -112.71%-265K | -226.57%-805K | -65.26%1.44M | 68.45%1.36M | -228.40%-5.5M | 24.40%2.09M | 140.87%636K | 75.31%4.14M | 107.91%805K | 70.25%-1.68M |
| -Change in receivables | 112.14%144K | -84.78%95K | 96.71%2.99M | -126.98%-58K | 78.95%-1.01M | -124.62%-1.19M | 108.55%624K | -79.79%1.52M | 114.66%215K | -20.36%-4.82M |
| -Change in inventory | -12.76%465K | 71.28%-222K | -138.95%-904K | 17.53%1.72M | -254.46%-358K | 427.72%533K | -122.33%-773K | 216.34%2.32M | 116.13%1.47M | 97.64%-101K |
| -Change in payables | -131.92%-874K | -186.37%-678K | -314.67%-644K | 64.73%-309K | -227.41%-4.13M | 184.43%2.74M | -65.57%785K | 109.51%300K | -331.75%-876K | 22.66%3.24M |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | 50.00%-20K | 21.43%-22K | -4.76%-22K | -43.10%-83K | 142.86%6K | -385.71%-40K | 34.88%-28K | -40.00%-21K | 15.94%-58K | 0.00%-14K |
| Interest received (cash flow from operating activities) | -66.67%23K | -80.15%26K | -12.90%27K | 182.35%336K | 191.67%105K | 291.67%69K | 42.39%131K | 14.81%31K | 119K | 36K |
| Tax refund paid | -115.07%-153K | 52.26%-169K | 51.82%-146K | 116.10%293K | 77.89%-65K | 245.24%1.02M | 69.92%-354K | 52.88%-303K | 3.81%-1.82M | 71.65%-294K |
| Other operating cash inflow (outflow) | 0 | 0 | 0 | 0 | -1K | 1K | 0 | 0 | 0 | 0 |
| Operating cash flow | -37.24%1.69M | -34.66%984K | -36.18%2.24M | 70.44%3.15M | -1,121.12%-4.57M | 958.43%2.7M | 447.64%1.51M | 107.57%3.51M | 125.32%1.85M | 93.31%-374K |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | 97.27%-37K | -108.33%-25K | -577.78%-61K | -15.69%-472K | 22,725.00%905K | -34,000.00%-1.36M | 96.92%-12K | 52.63%-9K | 28.30%-408K | 98.62%-4K |
| Net investment product transactions | 13.24%-2M | --999K | 72.97%-1M | -203.82%-3.9M | 1,153.00%2.11M | -1,252.00%-2.3M | --0 | -1,329.24%-3.7M | -112.34%-1.28M | -103.74%-200K |
| Dividends received (cash flow from investment activities) | --0 | 200.00%1K | --0 | 0.00%1K | -99.86%2K | --0 | ---1K | --0 | 0.00%1K | -0.07%1.41M |
| Interest received (cash flow from investment activities) | ---- | ---- | ---- | -5.04%113K | ---- | ---- | ---- | ---- | 36.78%119K | ---- |
| Investing cash flow | 44.39%-2.04M | 8,225.00%975K | 71.39%-1.06M | -170.91%-4.26M | 135.57%3.13M | -1,894.61%-3.66M | 99.39%-12K | -228.52%-3.71M | -115.84%-1.57M | -79.77%1.33M |
| Financing cash flow | ||||||||||
| Increase or decrease of lease financing | ---- | ---- | ---- | -17.97%-407K | ---- | ---- | ---- | ---- | -10.58%-345K | ---- |
| Cash dividends paid | --0 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%-1.41M | ---- |
| Net other fund-raising expenses | -52.24%-102K | 18.49%-97K | 12.50%-105K | -17.97%-407K | -13.48%-101K | -175.28%-67K | 54.41%-119K | -42.86%-120K | ---345K | ---89K |
| Financing cash flow | -52.24%-102K | -1,168.07%-1.51M | 12.50%-105K | 76.84%-407K | 93.27%-101K | -175.28%-67K | 54.41%-119K | -42.86%-120K | -1.91%-1.76M | -0.47%-1.5M |
| Net cash flow | ||||||||||
| Beginning cash position | -14.20%6.43M | -2.66%5.96M | -23.76%4.87M | -16.31%6.39M | -4.24%6.5M | 17.30%7.49M | -25.14%6.12M | -16.31%6.39M | 14.11%7.63M | -16.59%6.79M |
| Current changes in cash | 56.85%-444K | -67.27%450K | 436.68%1.07M | -2.30%-1.52M | -181.39%-1.54M | -287.77%-1.03M | 170.19%1.38M | -166.74%-319K | -264.74%-1.48M | -3.79%-548K |
| Effect of exchange rate changes | -106.06%-2K | --23K | -76.00%12K | -101.27%-3K | -157.33%-86K | 122.00%33K | --0 | -20.63%50K | 424.44%236K | 500.00%150K |
| End cash Position | -7.94%5.98M | -14.20%6.43M | -2.66%5.96M | -23.76%4.87M | -23.76%4.87M | -4.24%6.5M | 17.30%7.49M | -25.14%6.12M | -16.31%6.39M | -16.31%6.39M |
| Free cash flow | 23.38%1.66M | -35.81%959K | -37.76%2.18M | 85.96%2.68M | -868.78%-3.66M | 418.53%1.34M | 1,410.53%1.49M | 109.39%3.5M | 118.00%1.44M | 93.63%-378K |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.